Hussman Strategic Advisors Inc. Has $3.88 Million Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

Hussman Strategic Advisors Inc. grew its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 50.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,600 shares of the biotechnology company’s stock after purchasing an additional 4,200 shares during the period. United Therapeutics comprises about 0.9% of Hussman Strategic Advisors Inc.’s investment portfolio, making the stock its 12th biggest position. Hussman Strategic Advisors Inc.’s holdings in United Therapeutics were worth $3,884,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of UTHR. Norges Bank acquired a new stake in United Therapeutics in the 4th quarter worth $151,764,000. FMR LLC lifted its holdings in shares of United Therapeutics by 36.5% during the 4th quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after acquiring an additional 393,777 shares during the period. Vaughan Nelson Investment Management L.P. bought a new position in shares of United Therapeutics during the 1st quarter worth about $101,354,000. GAMMA Investing LLC lifted its holdings in United Therapeutics by 29,415.2% during the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company’s stock valued at $68,422,000 after purchasing an additional 221,202 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in United Therapeutics by 28.5% during the 4th quarter. Alliancebernstein L.P. now owns 709,043 shares of the biotechnology company’s stock valued at $250,179,000 after purchasing an additional 157,363 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In related news, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the sale, the director directly owned 19,384 shares in the company, valued at $5,613,606.40. This trade represents a 13.54% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James Edgemond sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the transaction, the chief financial officer owned 8,118 shares in the company, valued at $2,641,353.66. This trade represents a 59.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold 73,681 shares of company stock valued at $22,140,089 in the last quarter. Company insiders own 10.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on UTHR. HC Wainwright reissued a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. JPMorgan Chase & Co. dropped their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research note on Tuesday, July 8th. Bank of America dropped their target price on shares of United Therapeutics from $321.00 to $315.00 and set a “neutral” rating for the company in a research note on Wednesday, June 11th. Wall Street Zen downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $314.00 target price (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $383.08.

United Therapeutics Stock Performance

NASDAQ:UTHR traded down $2.43 during trading hours on Friday, hitting $294.90. The stock had a trading volume of 24,685 shares, compared to its average volume of 441,255. The business’s 50 day moving average is $300.61 and its 200-day moving average is $318.55. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $417.82. The company has a market cap of $13.30 billion, a price-to-earnings ratio of 11.77, a P/E/G ratio of 6.52 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to analysts’ expectations of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter last year, the company posted $6.17 earnings per share. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.